[Therapy of Antibody-Associated Autoimmune Encephalitis].
The identification of an antibody-associated autoimmune encephalitis underlying diverse syndromes, typically comprising epileptic seizures and neuropsychiatric symptoms, and their favorable prognosis, when treated with immunotherapies, is one of the success stories in neurology in recent years. Here we review current widely used therapy regimens in antibody-associated autoimmune encephalitis and the prognosis of the different antibody-associated sub-forms. The main therapeutic instruments encompass tumor therapy (if tumor is detected) and immunotherapies, though recommendations are mainly based on retrospective data analysis. The primary therapeutic goal is complete remission. The degree to which this can be accomplished depends upon the different sub-forms.
M
M
Malter
G R
GR
Fink
D001323:Autoantibodies / Q000097:blood*; D004660:Encephalitis / Q000276:immunology* / Q000628:therapy*; D004827:Epilepsy / Q000276:immunology* / Q000628:therapy*; D005968:Glutamate Decarboxylase / Q000276:immunology; D050031:Hashimoto Disease / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D047908:Intracellular Signaling Peptides and Proteins; D009419:Nerve Tissue Proteins / Q000276:immunology; D019965:Neurocognitive Disorders / Q000276:immunology* / Q000628:therapy*; D010257:Paraneoplastic Syndromes / Q000276:immunology / Q000628:therapy; D011379:Prognosis; D011506:Proteins / Q000276:immunology; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology
D001323:Autoantibodies; C485668:GRIN1 protein, human; D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; C116499:LGI1 protein, human; D009419:Nerve Tissue Proteins; D011506:Proteins; D016194:Receptors, N-Methyl-D-Aspartate; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2